Frankfurt - Delayed Quote ? EUR Novo Nordisk A/S (NOVA.F) Follow Compare 108.00 -1.00 (-0.92%) At close: 9:50 PM GMT+2 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Novo Nordisk's Rybelsus Sets New Standard: 14% Cut in Cardiovascular Risks for Diabetics SOUL Trial Results Position Rybelsus as a Game-Changer in Diabetes and Cardiovascular Care, Poised for Expanded U.S. and E.U. Approval GuruFocus.com ? 7 hours ago NVO NVO Stock Falls 5% in a Month: Should Investors Buy Now or Wait? Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs. Zacks ? 7 hours ago NVO NVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B The CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk's Alhemo for haemophilia A or B with inhibitors. Zacks ? 8 hours ago NVO ALNY The pill form of Ozempic can reduce the risk of heart attacks and strokes, study says The pill version of Novo Nordisk’s (NVO) blockbuster drug Ozempic was found to cut the risk of heart attacks, strokes, and other cardiovascular events in a late-stage clinical trial. Quartz ? 9 hours ago NVO LLY I'm a pharmacist. Knockoff Ozempic and other weight loss products have serious hidden risks In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to control blood sugar levels and reduce the risk of heart disease. Quartz ? 10 hours ago NVO LLY Novo Nordisk A/S - share repurchase programme Bagsv?rd, Denmark, 21 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme i GlobeNewswire ? 11 hours ago NONOF NVO Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart Attacks, Stroke Events By 14% On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial. Last year, Novo Nordisk’s subcutaneous once-weekly (injectable) semaglutide 2.4 mg, available as Wegovy, showed a 20% reduction in MACE compared to placebo. The SOUL trial compared oral semaglutide to placebo as an adjunct to the standard of care to prevent major adverse cardiovascular events (MACE), such as cardiac arrest, stroke, heart failure, or cardiovascular death. The Benzinga ? 11 hours ago NVO Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial Bagsv?rd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). The trial enrolled 9,650 people with type 2 diabetes and established cardiovascular disease (CVD) and/or chronic kidney disease (CKD). As part of standard of care, 49% of patients received SGLT2 GlobeNewswire ? 14 hours ago NONOF NVO Europe Drug Regulator's Advising Panel Recommends Approval Of Novo Nordisk's Australia-Approved Hemophilia Drug On Friday, Novo Nordisk A/S (NYSE:NVO) said that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for hemophilia patients aged 12 years or older, with A or B with inhibitors. Haemophilia is a rare bleeding disorder that impairs the body’s ability to make blood clots, a process needed to stop bleeding. Also Read: Novo Nordi Benzinga ? 3 days ago NVO European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock PREMIUM MT Newswires ? 3 days ago CTLT NVO Discover October 2024's Stocks Estimated To Be Trading Below Fair Value As global markets navigate a complex landscape marked by record highs in U.S. indices and mixed economic signals from Europe and China, investors are keenly observing the implications of modestly higher inflation and shifting interest rate expectations. Amidst this dynamic environment, identifying stocks that may be trading below their fair value can offer potential opportunities for those looking to capitalize on market inefficiencies. Simply Wall St. ? 3 days ago CLLNY CLNXF NONOF Novo Nordisk A/S: Alhemo? recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors Bagsv?rd, Denmark, 18 October 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval of Alhemo? (concizumab) as the first once-daily subcutaneous prophylactic treatment for people aged 12 years or older living with haemophilia A or B with inhibitors. Haemophilia is a rare bleeding disorder that impairs the body’s ability to make blood clots, a process needed to stop GlobeNewswire ? 3 days ago NONOF NVO Jim Cramer Says Novo Nordisk A/S (NVO) ‘Doesn’t Hold A Candle To Eli Lilly’ We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks discussed by Jim Cramer during the latest lightning round. On Tuesday, Jim Cramer, host of Mad Money, shared his thoughts […] Insider Monkey ? 3 days ago NVO LLY ^GSPC Consumer groups ask FTC to block Novo Holdings-Catalent deal NEW YORK (Reuters) -U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk, from acquiring contract drug manufacturer Catalent, saying the deal threatens competition in weight loss drugs and cutting-edge gene therapies. U.S. Public Interest Research Group, Service Employees International Union (SEIU) and others expressed concerns in a letter to the FTC about the $16.5 billion deal, which Novo Holdings has said would boost supply of Wegovy, Novo's blockbuster GLP-1 injectable weight-loss drug. Last week, U.S. Senator Elizabeth Warren, a Democrat, called on the FTC to look closely at the deal over similar concerns. Reuters ? 4 days ago CTLT NVO Ozempic and other weight loss drugs could help treat alcohol and drug addiction, study says The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger. Quartz ? 4 days ago NVO Is Eli Lilly Stock A Buy After Snagging Approval For A New Eczema Drug? The Food and Drug Administration signed off on a new eczema drug from Eli Lilly. Is Eli Lilly stock a buy right now? Investor's Business Daily ? 4 days ago LLY NVO BIIB Investors must 'be wary' how interest rates impact this market: Strategist The Russell 2000 (^RUT) small-cap index has reached its highest level in three years, signaling a clear shift in market dynamics. MarketGauge.com chief strategist Michele Schneider joins Yahoo Finance's Morning Brief to share her insights on this market (^DJI, ^IXIC, ^GSPC) rotation and overall outlook. Schneider attributes the broadening market to investor sentiment around interest rates, suggesting that many believe "rates at least have peaked and will actually go down." While markets are hovering near all-time highs, she cautions investors to "be wary" of future interest rate trends — noting that October is historically a volatile month for markets. "We may need a little bit more patience," Schneider told Yahoo Finance, "to really see if this is a sustainable broadening. Certainly, it is a bullish season after two years of a bull market. By the third year, it generally goes up. We're optimistic, but we're not flying into everything yet." Regarding investment opportunities, Schneider highlights retail companies like Ulta Beauty (ULTA) and e.l.f. Beauty (ELF), as well as pharmaceutical giant Novo Nordisk (NVO). She describes these stocks as relatively "cheap," potentially offering attractive entry points for investors. In the tech sector (XLK), Schneider points to ASML Holding (ASML) as a promising option, noting that investors "cannot deny that that [the tech sector] is a growing field." To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Angel Smith Yahoo Finance Video ? 4 days ago XLK ASML ASMLF The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, PPH, HRTS and THNR Eli Lilly, Novo Nordisk, PPH, HRTS and THNR are part of the Zacks top Analyst Blog. Zacks ? 4 days ago NVO LLY Novo Nordisk A/S (NVO): Most Promising Future Stock According to Analysts We recently compiled a list of the 10 Most Promising Future Stocks According to Analysts. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other Most Promising Future Stocks According to Analysts. Rising Market Volatility Volatility in the equity markets is poised to hit levels not seen […] Insider Monkey ? 4 days ago NVO ^GSPC Is Novo Nordisk A/S (NVO)? the Most Promising Biotech Stock According to Hedge Funds? We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other promising biotech stocks. Biotechnology stocks are known for their high risk, making them some of the most volatile in the […] Insider Monkey ? 5 days ago NVO Performance Overview Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index Return NOVA.F OMX Copenhagen 25 Index YTD +17.53% +6.14% 1-Year +20.11% +19.92% 3-Year +151.91% -0.25%
